Dengue fever future or investigational therapies

Dengue Fever Microchapters
Home
Patient Info
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Dengue fever from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Dengue fever future or investigational therapies On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Dengue fever future or investigational therapies All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Dengue fever future or investigational therapies
CDC on Dengue fever future or investigational therapies
Dengue fever future or investigational therapies in the news
Blogs on Dengue fever future or investigational therapies
Directions to Hospitals Treating Dengue fever
Risk calculators and risk factors for Dengue fever future or investigational therapies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Although there is no commercially available vaccine, there are several ongoing vaccine development programs.

Vaccine development

There is no commercially available vaccine for the dengue flavivirus. However, one of the many ongoing vaccine development programs is the Pediatric Dengue Vaccine Initiative which was set up in 2003 with the aim of accelerating the development and introduction of dengue vaccine(s) that are affordable and accessible to poor children in endemic countries. Thai researchers are testing a dengue fever vaccine on 3,000-5,000 human volunteers within the next three years after having successfully conducted tests on animals and a small group of human volunteers. A number of other vaccine candidates are entering phase I or II testing. Sanofi reported that its vaccine was effective in a late stage program.

Inhibitors of Viral Replication

Emerging evidence suggests that mycophenolic acid and ribivirin inhibit Dengue fever virus replication. Initial experiments showed a fivefold increase in defective viral RNA production by cells treated with each drug.^[2] In vivo studies, however, have not yet been done.